论文部分内容阅读
目的:对还原型谷胱甘肽在酒精性肝病患者的临床治疗效果进行分析与观察。方法:选取2012年10月至2014年9月收治的酒精性肝病患者72例作为研究对象,随机分为对照组和实验组各36例,给予对照组患者常规治疗方法,在对照组的治疗基础上给予实验组患者还原型谷胱甘肽的治疗。对两组患者的治疗总有率以及丙氨酸氨基转移酶(ALT)、白蛋白(ALB)、天门冬氨酸氨基转移酶(AST)以及总胆红素(TBIL)等生化指标进行对比分析。结果:对照组的治疗总有效率为83.3%,治疗组的治疗总有效率为97.2%,两组相比,差异具有统计学意义(P<0.05);在ALT、ALB、AST以及TBIL生化指标方面,治疗后优于治疗前,且治疗组优于对照组,差异具有统计学意义(P<0.05)。结论:针对酒精性肝病患者进行还原型谷胱甘肽的治疗所具有的临床效果显著。
Objective: To analyze and observe the clinical effect of reduced glutathione in patients with alcoholic liver disease. Methods: Seventy-two patients with alcoholic liver disease admitted from October 2012 to September 2014 were randomly divided into control group and experimental group, with 36 cases in each group. The patients in control group were given routine treatment, On the experimental group patients treated with reduced glutathione. The total treatment rate and the biochemical indexes such as ALT, AST, AST and TBIL of the two groups were compared . Results: The total effective rate of the control group was 83.3%, the total effective rate of the treatment group was 97.2%, the difference was statistically significant (P <0.05); in the ALT, ALB, AST and TBIL biochemical indicators After treatment, the treatment group was superior to the control group, the difference was statistically significant (P <0.05). Conclusion: The clinical effect of reducing glutathione in patients with alcoholic liver disease is significant.